About Tarix Pharmaceuticals
Tarix Pharmaceuticals is a clinical stage biopharmaceutical company developing peptide drugs, TXA127 and PanCyte, to address significant unmet medical needs. These peptides are components of the ACE2/Angiotensin (1-7)/Mas pathway in the renin angiotensin system (RAS). We are investigating the use of the peptides in three principal therapeutic areas:
- Ischemic diseases: ischemic stroke recovery, peripheral vascular disease
- Metabolic disease: Type 2 diabetes
- Hematopoiesis: stem cell transplantation, thrombocytopenia
TXA127 is a pharmaceutical formulation of the naturally occurring peptide, Angiotensin (1-7). PanCyte is a cyclic analogue of TXA127 with an extended half-life. TXA127 and PanCyte have shown striking effects in models of ischemic stroke and peripheral vascular disease, through improvement in endothelial progenitor cell number and function. The peptides have also been effective in models of diabetes. Tarix intends to initiate clinical trials in these indications during 2013.
TXA127 has completed a Phase II trial in chemotherapy-induced thrombocytopenia, and is being evaluated for its ability to enhance engraftment of platelets and white blood cells, and for its ability to reduce GVHD and mucositis, in patients undergoing cord blood or peripheral blood stem cell transplantation.